scholarly journals Virologic and Clinical Outcomes of Hepatitis B Virus Infection in Recipients Undergoing Unrelated-Donor Hematopoietic Stem Cell Transplantation

2011 ◽  
Vol 17 (2) ◽  
pp. S303
Author(s):  
Y. Luo ◽  
Y. Hu ◽  
Y. Tan ◽  
X. Lai ◽  
J. Shi ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hepatitis B Virus ◽  
Hematopoietic Stem Cell Transplantation ◽  
Virus Infection ◽  
Hepatitis B ◽  
Stem Cell Transplantation ◽  
Unrelated Donor ◽  
Hepatitis B Virus Infection ◽  
Hematopoietic Stem ◽  
B Virus

scholarly journals A Comparison of Lamivudine and Entecavir for the Prophylaxis of Hepatitis B Virus Reactivation in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation: A Single Institutional Experience

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 2026-2026
Author(s):  
Jin Shang ◽  
Jing Sun ◽  
Zhiping Fan ◽  
Fen Huang ◽  
Yu Zhang ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hepatitis B Virus ◽  
Hematopoietic Stem Cell Transplantation ◽  
Hepatitis B ◽  
Stem Cell Transplantation ◽  
Hbv Reactivation ◽  
Post Transplantation ◽  
Hematopoietic Stem ◽  
B Virus ◽  
Cumulative Rate

Abstract Backgroud: To compare the efficacy of lamivudine and entecavir in the prevention of hepatitis B virus (HBV) reactivation in HBsAg-positive patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Method: A total of 216 consecutive HBV surface antigen (HBsAg) positive patients undergoing allo-HSCT at our institute between March 2008 and March 2014 were enrolled in this retrospective investigation. Results: Of the 216 patients, 119 received lamivudine and 97 received entecavir to prevent HBV reactivation. The cumulative rate of HBV reactivation at 24 th, 48 th, and 96 th post-transplantation were 7.0% and 0.0%, 15.0% and 1.0%, and 24.0% and 2.0% in lamivudine and entecavir groups, respectively. The cumulative rate of severe hepatitis attributable to HBV reactivation were 5.9% and 0.0% (p = 0.01) in lamivudine and entecavir groups at week 96 post-transplantation, respectively. On the 12th, 24th, and 48th weeks of anti-viral therapythe average serum HBV-DNA levels reduction in entecavir group were greater than in the lamivudine Drug-resistant mutation sites were detected in 25 (21.0%) patients in the lamivudine group and in one patient (1.0%) in the entecavir group. Conclusion: Our data indicates that entecavir might reduce the incidence of HBV reactivation and severe HBV reactivation hepatitis in HBsAg-positive allo-HSCT recipients compared to lamivudine. Disclosures No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document